The cleanest GH secretagogue — selective release without cortisol or prolactin spikes in preclinical models. 30+ peer-reviewed studies. 99%+ HPLC-verified purity. 3-lab independent COA on every batch.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates pulsatile GH release from the anterior pituitary. Unlike older GH secretagogues such as GHRP-2 and GHRP-6, ipamorelin produces a cleaner GH pulse — preclinical studies demonstrate selective GH release without significant elevation of cortisol, prolactin, or ACTH.
This selectivity makes ipamorelin one of the most widely studied GH secretagogues in body composition, bone density, and sleep architecture research models. It acts on the ghrelin/GHSR-1a receptor with high specificity, producing dose-dependent GH release that mimics physiological pulsatility.
Ipamorelin is classified as a research-use-only compound. It is not FDA-approved for any therapeutic indication. All references below describe preclinical (in vitro or animal model) research contexts, not human clinical outcomes.
Studied for its ability to stimulate growth hormone secretion without concomitant elevation of cortisol or prolactin — a key differentiator from GHRP-2 and GHRP-6 in preclinical comparisons.
Preclinical research examines ipamorelin's effects on lean mass preservation and fat mass reduction through pulsatile GH signaling, particularly in aging and metabolic disruption models.
Multiple publications investigate ipamorelin's role in osteoblast activity and bone mineral density signaling in osteopenia models, with particular interest in age-related bone loss prevention.
Research explores ipamorelin's influence on slow-wave sleep patterns through GH pulsatility modulation, examining the relationship between GH secretion timing and sleep quality markers.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates pulsatile GH secretion from the anterior pituitary without elevating cortisol or prolactin. It is one of the cleanest GH secretagogues studied in preclinical literature, acting specifically on the ghrelin/GHSR-1a receptor.
In preclinical models, ipamorelin produces selective GH release without significant cortisol or prolactin elevation — unlike GHRP-2 and GHRP-6 which can stimulate broader hormonal responses. This selectivity makes ipamorelin preferred in research requiring isolated GH pathway study.
Ipamorelin + CJC-1295 is one of the most commonly researched GH peptide combinations. CJC-1295 (a GHRH analog) amplifies the GH pulse initiated by ipamorelin (a GHRP), producing synergistic GH elevation in preclinical models. SMART MD carries both compounds individually for researchers.
Research-grade Ipamorelin with 3-lab COA verification is available at SMART MD Peptides in a 10mg formulation. Every batch is publicly verifiable at smartmdpeptides.com/verify before purchase. 99%+ HPLC purity guaranteed.
Lyophilized (unreconstituted) Ipamorelin should be stored at -20°C, protected from light. Once reconstituted, store at 2-8°C and use within the timeframe specified on your lot-specific documentation.
Check the COA before you buy. Compare it against any other supplier's documentation.